Impact of Vaccines; Health, Economic and Social Perspectives.

Rodrigues CMC, Plotkin SA. · 2020

Read Impact of Vaccines; Health, Economic and Social Perspectives. by Rodrigues CMC, Plotkin SA. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7371956.txt.

Introduction

Rodrigues and Plotkin survey the full value of vaccines in Frontiers in Microbiology, across health, money, and society. Systematic vaccination drives in the twentieth century began closing global gaps in protection against deadly infections. Access remains unequal, which the authors, a clinician and a leading vaccine scientist, treat as the core problem.

Beyond preventing illness and death, vaccines save treatment costs, keep parents at work, and support schooling and social stability. Benefits reach all regions and age groups, the evidence they gather shows. The piece was written as COVID-19 vaccine work raced ahead at record speed. The authors urge that the wider benefits be measured and communicated to the public and policymakers.

Catalog record

CREATORRodrigues CMC, Plotkin SA.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE78 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7371956

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Impact of Vaccines; Health, Economic and Social Perspectives By Charlene M. C. Rodrigues, Stanley A. Plotkin Published in: Frontiers in Microbiology DOI: 10.3389/fmicb.2020.01526 ABSTRACT In the 20th century, the development, licensing and implementation of vaccines as part of large, systematic immunization programs started to address health inequities that existed globally. However, at the time of writing, access to vaccines that prevent life-threatening infectious diseases remains unequal to all infants, children and adults in the world. This is a problem that many individuals and agencies are working hard to address globally. As clinicians and biomedical scientists we often focus on the health benefits that vaccines provide, in the prevention of ill-health and death from infectious pathogens. Here we discuss the health, economic and social benefits of vaccines that have been identified and studied in recent years, impacting all regions and all age groups. After learning of the emergence of SARS-CoV-2 virus in December 2019, and its potential for global dissemination to cause COVID-19 disease was realized, there was an urgent need to develop vaccines at an unprecedented rate and scale. As we appreciate and quantify the health, economic and social benefits of vaccines and immunization programs to individuals and society, we should endeavor to communicate this to the public and policy makers, for the benefit of endemic, epidemic, and pandemic diseases. INTRODUCTION “The impact of vaccination on the health of the world’s peoples is hard to exaggerate. With the exception of safe water, no other modality has had such a major effect on mortality reduction and population growth” (Plotkin and Mortimer, 1988). The development of safe and efficacious vaccination against diseases that cause substantial morbidity and mortality has been one of the foremost scientific advances of the 21st century. Vaccination, along with sanitation and clean drinking water, are public health interventions that are undeniably responsible for improved health outcomes globally. It is estimated that vaccines have prevented 6 million deaths from vaccine-preventable diseases annually (Ehreth, 2003). By 2055, the earth’s population is estimated to reach almost 10 billion (United Nations Department of Economic and Social Affairs, 2019), a feat that in part is due to effective vaccines that prevent disease and prolong life expectancy across all continents. That said, there is still much to be done to ensure the financing, provision, distribution, and administration of vaccines to all populations, in particular those which are difficult to reach, including those skeptical about their protective value and those living in civil disruption. Agencies including the World Health Organization (WHO), United Nations Children’s Fund (UNICEF), Gavi, the Vaccine Alliance, The Bill & Melinda Gates Foundation, and the Coalition for Epidemic Preparedness Initiative (CEPI), with their multiple funding streams have been instrumental in expanding vaccine benefits to all. These importance of these organizations in global co-operation and participation was essential in the setting of the 2019 global pandemic of SARS-CoV-2, in light of the health and economic impact of COVID-19 on societies in high-, middle- and low-income countries. This review will highlight the benefits of vaccinations to society from the perspectives of health, economy, and social fabric (Figure 1), which need to be considered in the overall assessment of impact to ensure that vaccines are prioritized by those making funding decisions. [Figure: The impact of vaccines according to their health, economic or social benefit.] BRIEF HISTORY OF VACCINE DEVELOPMENT Human use of preparations to prevent specific infections have been described since 1500 AD, beginning in China (Needham, 2000) where smallpox was prevented by variolation, which is the introduction of material from scabs into the skin. In 1796 in the United Kingdom, Edward Jenner observed the immunity to smallpox of milkmaids having previously had natural infection with cowpox (Jenner, 1798). He determined that inoculating small amounts of pus from the lesions of cowpox, presumably containing a virus related to vaccinia, into susceptible hosts rendered them immune to smallpox. The vaccine against smallpox was developed in 1798. The next phase of scientific developments involving the manipulation of infectious agents to extract suitable vaccine antigens took almost a century of research. Louis Pasteur’s work with attenuation by oxygen or heat led to live-attenuated chicken cholera, inactivated anthrax and live-attenuated rabies vaccines at the turn of the 20th century (Pasteur, 1880, 1881, 1885). Alternative methods of attenuation using serial passage of Mycobacterium bovis led to the live Bacille Calmette-Guerin (BCG) (Calmette, 1927) vaccine, still in use today for the prevention of tuberculosis. Serial passage was also used in the development of yellow fever vaccines (Theiler and Smith, 1937a) which are grown in chicken embryo tissues (Theiler and Smith, 1937b). Whole cell killed bacterial vaccines were developed when methods to treat and kill bacteria through heat or chemicals were established and whole cell typhoid, cholera and pertussis vaccines resulted at the end of the 19th Century. In 1923, Alexander Glenny and Barbara Hopkins developed methods to inactivate bacterial toxins with formaldehyde, leading to the diphtheria and tetanus toxoid vaccines (Glenny and Hopkins, 1923). Advances in virus culture in vitro allowed viral pathogens to be studied in greater detail and attenuation methods due to cultivation in artificial conditions led to the live oral polio, measles, rubella, mumps and varicella virus vaccines. In the 1960’s at the Walter Reed Army Institute of Research, vaccines were developed using capsular polysaccharides (Gold and Artenstein, 1971; Artenstein, 1975), of encapsulated organisms including meningococci and later pneumococci (Austrian, 1989) and Haemophilus influenzae type b (Hib) (Anderson et al., 1972). To protect against multiple serotype variants of polysaccharide capsules, polyvalent vaccines were developed and later conjugated to carrier proteins to enhance their efficacy in infants in particular by recruiting T-cell mediated help to induce memory B-cells (Schneerson et al., 1980). Vaccines made solely from proteins were rare, with the exception of the toxoid vaccines, but the acellular pertussis vaccine containing five protein antigens, was developed to mitigate the unwanted effects of the whole cell vaccine (Sato and Sato, 1999). The end of the 20th century marked a revolution in molecular biology and provided insights into microbiology and immunology allowing a greater understanding of pathogen epitopes and host responses to vaccination. Molecular genetics and genome sequencing has enabled the development of vaccines against RNA viruses possessing multiple variants of epitopes, such as the live and inactivated influenza vaccines (Maassab and DeBorde, 1985) and live rotavirus vaccines (Clark et al., 2006). DNA manipulation and excision allowed the use of surface antigen for hepatitis B viral vectors (Plotkin, 2014). The human papilloma virus (HPV) vaccine benefits from enhanced immunogenicity due to the formation of virus-like particles by the L1 antigen of each virus contained in the vaccine (Kirnbauer et al., 1992). Bacterial genome sequencing has provided in depth analysis of meningococcal antigens, to identify potential proteins for meningococcal B vaccines (Serruto et al., 2012). Vaccine development was tested in 2020 when a novel coronavirus, SARS-CoV-2, emerged from China causing a severe acute respiratory illness, which subsequently spread globally. Within 5 months of the discovery of this virus (7th January 2020) (Zhu et al., 2020) and person-person transmission (Chan et al., 2020), 5,697,334 cases had been identified, with orders of magnitude likely not measured and almost no country escaped the pandemic. Owing to the previous advances in vaccinology, by 8th April

Read the complete text